Lucid Diagnostics (LUCD) Share-based Compensation (2020 - 2026)

Lucid Diagnostics (LUCD) has 7 years of Share-based Compensation data on file, last reported at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 36.99% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (up 7.34% YoY), and the FY2025 full-year result was $4.5 million, down 0.95% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.4 million, up from $1.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $3.8 million in Q2 2022 and bottomed at -$97000.0 in Q4 2023.
• The 5-year median for Share-based Compensation is $1.3 million (2023), against an average of $1.8 million.
• The widest annual swing landed in 2023, when Share-based Compensation tumbled 102.78%; it then jumped 1307.22% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $3.5 million in 2022, then tumbled by 102.78% to -$97000.0 in 2023, then surged by 1307.22% to $1.2 million in 2024, then gained by 7.94% to $1.3 million in 2025, then grew by 11.63% to $1.4 million in 2026.
• The last three Share-based Compensation figures came in at $1.4 million (Q1 2026), $1.3 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.

Peer Comparison